Trending...
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
PITTSBURGH--(BUSINESS WIRE)--Rimsys, the leading provider of Regulatory Information Management (RIM) software for the medtech industry, today announced the release of the 2023 Regulatory Performance Report, a new study that tracks trends in regulatory priorities, processes, and performance within medtech companies. The report is based on a survey of 200 regulatory professionals and executives across North America and Europe.
The report explores how regulatory affairs teams are staffed, their workload, average times to complete regulatory projects, where they experience compliance issues, and the growing trend of accelerating digital transformation within the industry.
"The need for this report was driven by conversations with several of our customers," said James Gianoutsos, Founder and CEO of Rimsys. "Regulatory leaders don't have clear benchmarks to measure the performance of their teams. They're looking at digital transformation initiatives to improve the efficiency and effectiveness of their teams and want to understand what's possible, what really good execution looks like."
Key findings include:
Regulatory teams are lightly staffed compared to their workload.
A quarter of large medtech companies have 15 or fewer regulatory employees. These small teams complete over 100 renewals or license updates each year. Only 13% of companies make resourcing decisions based on anticipated workload, leaving any gaps to be filled with external consultants. Today, 90% of companies rely on consultants to complete regulatory projects.
Process failures are common.
Regulatory leaders self-assess the performance of their teams highly. A majority believe they outperform other regulatory affairs teams in similar companies in both project planning and execution. Yet over 60% reported a major non-compliance issue in that past year, and 24% had to withdraw products from a country or region due to non-compliance.
More on The PennZone
Digital transformation makes a measurable impact on productivity.
Companies are investing in process improvement, both by increasing staffing and growing technology budgets. They are moving away from generic productivity tools to more specialized solutions designed for regulatory processes. Companies that have implemented regulatory information management and regulatory intelligence systems report very high productivity gains and they complete regulatory projects more quickly.
Rimsys and PA Consulting, a global innovation and transformation consultancy, in conjunction with the Regulatory Affairs Professionals Society, will be presenting and discussing the survey findings in an interactive webinar on February 23, 2023. To attend, register here: https://bit.ly/performance-study-webinar.
"A major trend we are tracking this year is focused on Medtech's engagement with regulatory bodies against a backdrop of new requirements for advanced technologies such as AI, and evolving legislation such as the MDR and IVDR transition in Europe. This has forced organizations to re-evaluate old processes and adopt new tools," said Marck Aghnatios, MedTech Expert at PA Consulting. "The impact of this change will be largely absorbed by the regulatory affairs function – which is accurately reflected Rimsys' study findings. The industry imperative for medtech leaders will be to digitize their business functions – starting with regulatory."
Methodology
More on The PennZone
Rimsys worked with a third-party market research firm to field and administer the survey in July 2022. Survey respondents included 200 regulatory professionals at medtech (medical device, in vitro diagnostic, and software as a medical device) companies headquartered in the United States, Canada, and the European Union. Companies were evenly sampled across all sizes, from $10 million to more than $1 billion in revenue.
To download the full Regulatory Performance report, please visit: https://www.rimsys.io/regulatory-performance-report.
About Rimsys
Rimsys is improving global health by accelerating delivery and increasing availability of life-changing medical technologies. Rimsys Regulatory Information Management (RIM) software digitizes and automates regulatory activities, helping medtech regulatory affairs teams to plan more effectively, execute more quickly, and confidently ensure global regulatory compliance. Unlike complex, color-coded spreadsheets, or expensive external consultants, Rimsys centralizes all regulatory information, automates submission processes, and provides detailed visibility into product registrations, expirations, relevant standards, and global regulations. Traditional approaches to regulatory affairs can't keep pace with the growing complexity of the global landscape, and overburdened teams face increasing compliance risks. Rimsys is designed around medtech regulations and workflows and supports a full breadth of regulatory activities including registrations, submissions, UDI, essential principles, standards management, and regulatory intelligence in a single, integrated platform. Leading global medtech companies including Johnson & Johnson, Siemens Healthineers, and Omron rely on Rimsys to better manage regulatory projects and resources, get new products to market more quickly, and reduce revenue risk of non-compliance, product recalls, and unexpected expirations. For more information, visit www.rimsys.io.
Contacts
Michael Peach
(855) 846-7269
michael.peach@rimsys.io
The report explores how regulatory affairs teams are staffed, their workload, average times to complete regulatory projects, where they experience compliance issues, and the growing trend of accelerating digital transformation within the industry.
"The need for this report was driven by conversations with several of our customers," said James Gianoutsos, Founder and CEO of Rimsys. "Regulatory leaders don't have clear benchmarks to measure the performance of their teams. They're looking at digital transformation initiatives to improve the efficiency and effectiveness of their teams and want to understand what's possible, what really good execution looks like."
Key findings include:
Regulatory teams are lightly staffed compared to their workload.
A quarter of large medtech companies have 15 or fewer regulatory employees. These small teams complete over 100 renewals or license updates each year. Only 13% of companies make resourcing decisions based on anticipated workload, leaving any gaps to be filled with external consultants. Today, 90% of companies rely on consultants to complete regulatory projects.
Process failures are common.
Regulatory leaders self-assess the performance of their teams highly. A majority believe they outperform other regulatory affairs teams in similar companies in both project planning and execution. Yet over 60% reported a major non-compliance issue in that past year, and 24% had to withdraw products from a country or region due to non-compliance.
More on The PennZone
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
- Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
- Ezra Wohlgelernter Installed Philadelphia Bar Association Chancellor
- Power Couple Launches "Happy Habits Events" After Best of Philly Win, Pandemic Loss, and Setbacks
Digital transformation makes a measurable impact on productivity.
Companies are investing in process improvement, both by increasing staffing and growing technology budgets. They are moving away from generic productivity tools to more specialized solutions designed for regulatory processes. Companies that have implemented regulatory information management and regulatory intelligence systems report very high productivity gains and they complete regulatory projects more quickly.
Rimsys and PA Consulting, a global innovation and transformation consultancy, in conjunction with the Regulatory Affairs Professionals Society, will be presenting and discussing the survey findings in an interactive webinar on February 23, 2023. To attend, register here: https://bit.ly/performance-study-webinar.
"A major trend we are tracking this year is focused on Medtech's engagement with regulatory bodies against a backdrop of new requirements for advanced technologies such as AI, and evolving legislation such as the MDR and IVDR transition in Europe. This has forced organizations to re-evaluate old processes and adopt new tools," said Marck Aghnatios, MedTech Expert at PA Consulting. "The impact of this change will be largely absorbed by the regulatory affairs function – which is accurately reflected Rimsys' study findings. The industry imperative for medtech leaders will be to digitize their business functions – starting with regulatory."
Methodology
More on The PennZone
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club
- A New Soul Album: Heart Of Kwanzaa, 7-Day Celebration
- Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
Rimsys worked with a third-party market research firm to field and administer the survey in July 2022. Survey respondents included 200 regulatory professionals at medtech (medical device, in vitro diagnostic, and software as a medical device) companies headquartered in the United States, Canada, and the European Union. Companies were evenly sampled across all sizes, from $10 million to more than $1 billion in revenue.
To download the full Regulatory Performance report, please visit: https://www.rimsys.io/regulatory-performance-report.
About Rimsys
Rimsys is improving global health by accelerating delivery and increasing availability of life-changing medical technologies. Rimsys Regulatory Information Management (RIM) software digitizes and automates regulatory activities, helping medtech regulatory affairs teams to plan more effectively, execute more quickly, and confidently ensure global regulatory compliance. Unlike complex, color-coded spreadsheets, or expensive external consultants, Rimsys centralizes all regulatory information, automates submission processes, and provides detailed visibility into product registrations, expirations, relevant standards, and global regulations. Traditional approaches to regulatory affairs can't keep pace with the growing complexity of the global landscape, and overburdened teams face increasing compliance risks. Rimsys is designed around medtech regulations and workflows and supports a full breadth of regulatory activities including registrations, submissions, UDI, essential principles, standards management, and regulatory intelligence in a single, integrated platform. Leading global medtech companies including Johnson & Johnson, Siemens Healthineers, and Omron rely on Rimsys to better manage regulatory projects and resources, get new products to market more quickly, and reduce revenue risk of non-compliance, product recalls, and unexpected expirations. For more information, visit www.rimsys.io.
Contacts
Michael Peach
(855) 846-7269
michael.peach@rimsys.io
Filed Under: Business
0 Comments
Latest on The PennZone
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- The Rise of Experience Gifting: Families Choosing Memories Over More Stuff This Christmas
- Pittsburgh Family Law Firm Pollock Begg Elevates Two Attorneys to Partner Ranks
- Innovu Launches Auto Analysis, an AI Feature That Explains Healthcare Data in Plain Language
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
- MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
- From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Discover the Magic of Creativity with The Balance of Brushes and Bytes
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- BPM Systems Launches New Automated Packaging & Labeling Solution for Manufacturers Across The US
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)